Tesamorelin
Also known as · Egrifta
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
A stabilized GHRH analog FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy; studied for visceral fat more broadly.
Potent GHRH-receptor agonist that raises IGF-1 and preferentially reduces visceral fat.
1–2 mg subQ daily, typically evening.
Reconstituted: use promptly; refrigerate.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
CJC-1295
A long-acting GHRH analog (with DAC) that stimulates pulsatile growth-hormone release. Often stacked with Ipamorelin.
Ipamorelin
A selective ghrelin-receptor agonist that triggers GH release without raising cortisol or prolactin. Cleaner profile than older GHRPs.
Sermorelin
A GHRH (1-29) analog historically prescribed to assess and stimulate growth-hormone secretion. Short-acting and biomimetic.